Guinea: Reporter beaten up by President Alpha Condé’s bodyguards

first_img Help by sharing this information News Violence Violence June 30, 2016 Guinea: Reporter beaten up by President Alpha Condé’s bodyguards RSF_en center_img Reporters Without Borders (RSF) condemns journalist Abdoul Malick Diallo’s severe beating on 25 June by members of the presidential guard and calls for the punishment of those responsible. Organisation Diallo, who works for the weekly Le Populaire and the news website Aminata, was beaten repeatedly, first at the headquarters of RPG-Arc-en-Ciel, the ruling political party that President Alpha Condé continues to lead, and then at presidential guard headquarters, located inside the presidential palace. “Such acts of arbitrary violence against journalists are absolutely unacceptable, especially when they go unpunished, as they often do.” RSF said.“We call on the authorities to identify and punish the presidential guard members responsible for this attack.” Diallo went to the ruling party’s headquarter to cover its weekly general assembly and was stopped by a member of the presidential guard, a military unit known as the “Red Berets,” when he took a photo in the yard as President Condé was leaving. After first asking him to delete the photo, the soldier demanded the memory card and finally seized the camera. Condé’s presence at the meeting was problematic because article 38 of the constitution prohibits the president from participating in political party activities. It was at this point that several presidential guardsmen began beating Diallo and tearing his clothes. Then they threw him into a military vehicle, drove him to presidential guard headquarters and beat him even more severely there. They also insulted him in various ways including by means of derogatory references to his ethnicity. Guinea’s media associations told RSF they are outraged by the repeated violence against journalists and by what they consider to be President Condé’s repeated violations of the constitution. Diallo and his newspaper plan to file a complaint about the beating in the next few days. Journalists can pay dearly for criticism of the president. A court in Kankan (the capital of Haute Guinée province), located 650 km east of Conakry, fined Radio Milo FM journalist Malick Bouya Kébé 1 million Guinean francs (100 euros) on 22 June on a charge of “complicity in insulting the president.” Kébé, who was not defended by a lawyer, was accused of failing to turn off the microphone when a guest began criticizing the speech that President Condé gave at a political rally in Conakry on 28 May. The speech was discussed on virtually all of the country’s privately-owned radio stations but it was only in Kankan, the ruling party’s stronghold, that a court took it upon itself to hold a trial over an on-the-air comment. Guinea is ranked 108th out of 180 countries in RSF’s 2016 World Press Freedom Index. President Alpha Condé last_img read more

Press release: UK life sciences sector brings record growth as new Life Sciences Council meets for first time

first_imgnew research shows UK life sciences sector is soaring with record turnover of over £70 billion and SMEs accounting for 82% of businesses and 24% of all UK life sciences employment in 2017, the UK received the highest level of life science foreign direct investment projects in Europe – the highest in 7 years the new Council follows on from the transformative Life Sciences Sector Deal, part of the government’s modern Industrial Strategy, which drew substantial investment from 25 global companies Greg Clark, Business Secretary Jeremy Hunt, Health and Social Care Secretary Liam Fox, International Trade Secretary Lord O’Shaughnessy, Parliament Under Secretary of State for Health Simon Stevens, NHS England Kristen Mcleod, Office for Life Sciences Steve Oldfield, Department of Health and Social Care (DHSC) Sir Mark Walport, UK Research and Innovation (UKRI) Matthew Speers, Department for International Trade (DIT) Gareth Davies, Department for Business, Energy and Industrial Strategy (BEIS) Professor Chris Whitty, Department of Health & Social Care (DHSC) The UK has always been at the forefront of scientific innovation and research, developing ground-breaking treatments that can transform patients’ lives. The world-leading 100,000 Genomes Project, and the NHS Genomic Medicine Service that launches this autumn, are fantastic examples of our ambition to pioneer the most advanced approaches to healthcare in this country. Business Secretary Greg Clark said: The inaugural meeting of the new UK Life Sciences Council takes place today (16 May 2018). Business Secretary Greg Clark and Health and Social Care Secretary Jeremy Hunt will chair the Council, which will also be attended by a range of industry experts, including Pascal Soriot from AstraZeneca who will co-chair, J&J, MSD and ABPI. The main objective of the Council is to ensure the UK continues to be a global leader in life sciences.This comes as new research published today shows the UK continues to have one of the most productive health and life sciences sectors in the world. Health and life sciences are worth over £70 billion to the economy and provide jobs for almost 241,000 people across the country. The group will focus on progress in delivering the modern Industrial Strategy’s Life Sciences Sector Deal, launched in 2017, which will support the sector to develop and launch the next generation of medicines, technologies and diagnostics and provide better care and treatments for millions of patients.The fourth annual Life Science Competitiveness Indicators report also shows that the UK continues to attract significant private equity investment, with over £660 million invested in 67 UK projects in 2016. The UK also accounts for 12% of total life sciences academic citations and 18% of the most-cited publications, the 2nd highest share above China, Germany and Canada.Prime Minister Theresa May said: Bringing government, the NHS and industry together through the Council is an important step in ensuring the UK remains globally competitive in life sciences. We must all continue to work together through the Brexit negotiations to ensure the supply of medicines, regulatory alignment and the needs of patients remain priorities. Pascal Soriot, CEO of AstraZeneca Jean-Christophe Tellier, CEO and Chairman of the Executive Committee of UCB Mike Thompson, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI) Philip Thomson, President of GSK Peter Ellingworth, Chief Executive of Association of British Healthcare Industries (ABHI) Dr Roger Perlmutter, Executive Vice President of Merck & Co Michelle Brennan, President of Johnson & Johnson Group John Young, Group President of Pfizer Innovative Health Steve Bates, CEO of the UK BioIndustry Association Jackie Hunter, CEO of BenevolentBio Ltd Professor Sir John Bell, Life Sciences Champion Professor Jeremy Farrar, Director of The Wellcome Trust Haruo Naito, Director, Representative Corporate Officer and CEO of Eisai Co Michelle Brennan, EMEA Company Group Chair, Johnson & Johnson Medical Device Companies said: The modern Industrial Strategy sets out a long-term plan to boost the productivity and earning power of people throughout the UK. It sets out how we are building a Britain fit for the future – how we will help businesses create better, higher-paying jobs in every part of the UK with investment in skills, industries and infrastructure.The Industrial Strategy committed to increased government investment in R&D to 2.4% of GDP by 2027 and 3% over the longer term – delivering an estimated increase of £80 billion over the next 10 years. The Life Sciences Sector Deal set out plans for the Health Research Authority to speed up approvals for clinical trials.Additional quotes:ABPI CEO, Mike Thompson said: The UK continues to be a highly attractive destination for inward investment and global talent. With more than 5,000 life sciences companies and a strong culture of scientific innovation, our offer to the world as a global partner for investment and trade is clear. As the UK’s international economic department, the Department for International Trade promotes investment and export opportunities. We invite healthcare and life sciences innovators to work with us, driving growth in every part of the country. Global pharmaceutical companies are excited about UK science, our world leading Universities and unique research centres like the Crick Institute. The Life Sciences Council signals our joint commitment to implementing the Life Sciences Industrial Strategy to ensure the UK becomes a home for even more global companies to research, develop, manufacture and launch the next generation of medicines and vaccines. International Trade Secretary, Dr Liam Fox, said: allocating £30 million from a £100 million study to sequence the UK Biobank, providing a unique resource to identify new drug therapies and redefine the gold standard for genome sequencing announcing the world’s first study to establish centres of excellence in digital pathology and medical imaging in the NHS, which when set up will, using the digital images generated, help develop artificial intelligence (AI) algorithms for more accurate diagnosis of diseases, potentially improving NHS efficiencies in the process of creating up to 5 Digital Innovation Hubs across the UK, which will support the development of algorithms and machine learning for real-world studies and clinical trials. Being delivered by Professor Andrew Morris, Director of Health Data Research UK (HDRUK), the Hubs will enhance the UK’s global competitiveness in clinical trials and creating a unique business environment investing £65 million through the Industrial Strategy Challenge Fund to establish three advanced therapy treatment centres across the country, which will support medicine manufacturing and provide industry with access to cutting-edge technology to commercialise and develop innovations at scale Health Minister Lord O’Shaughnessy said: Industry I welcome the first meeting of the new Life Sciences Council today, which will drive research, development and innovation in this thriving sector far into the future. Further advancing the UK’s global leadership in life sciences is a key part of our modern Industrial Strategy – our plan for high-quality jobs and growth across the whole country. I am pleased to co-chair the new Life Sciences Council at an exciting but challenging time for the UK industry. With all the uncertainties of Brexit and patient access to medical innovations, the successful implementation of an ambitious industrial strategy is critical to ensure Britain remains a pioneer in life sciences and the sector continues to drive economic growth. With 2 Secretaries of State and industry leaders representing medical devices, biotech as well as pharmaceuticals, the new Life Sciences Council brings together expertise across UK life sciences to provide the strategic direction needed to thrive in the competitive global environment. As part of the Life Sciences Sector Deal, which brought together significant commitments and investments into the UK by 25 global organisations from across the sector, the government has worked closely with industry to deliver its strategic vision and in the last 6 months has launched major projects, including: From Edward Jenner developing the first successful small pox vaccine to Rosalind Franklin providing breakthrough research on the structure of DNA, UK life sciences have changed the world for the better. We are extraordinarily well placed to play a leading role in this revolution in the life sciences. Our universities and research institutes rank among the best in the world, nurturing and attracting some of the most inventive people on earth. Record turnover and foreign direct investment is a vote of confidence in the UK which we will build on as we work towards making Britain the best place in the world to develop and launch innovative medicines, technologies and diagnostics to help people live longer, healthier and happier lives. Notes to editorsFull list of Council attendeesGovernment I am delighted to be joining the Life Sciences Council, supporting the implementation of the Life Sciences Industrial Strategy in collaboration with our government partners. The Strategy is key to the UK remaining an attractive place for the Life Sciences industry to invest and to ensure that patients continue to benefit from the latest medical innovations. The NHS has an important role to play in the success of the strategy, with the potential to become an early adopter of new technologies and an engine for innovation and research. Johnson & Johnson is committed to working in partnership with both the NHS and government to make their ambition a reality. Pascal Soriot, industry co-chair of the Council, said: Phil Thomson, President, Global Affairs, GSK said:last_img read more

Panel discusses women’s experiences

first_imgBrown said she and her friends saw a woman at a market in Cairo wearing long shorts with her head uncovered being chased by men who were trying to grab her. Shresthova said that when volunteers and workers complete projects in developing countries, they must consider the local culture and speak with the people they are aiming to help. For one project in Nepal, she said they built water taps in villages so that women didn’t have to walk for hours to get water; however, the women were not happy.  At the event, Sarah Fisher, a graduate student studying public administration, asked how to approach women’s issues differently in someone’s home country versus a country with different customs and cultures.  The panel started off with each speaker introducing herself and telling stories about some of their trips and projects abroad. Shresthova said that when she was a dancer in India, her landlord scolded her when a male teacher drove her home from a performance during the day. The landlord told her that she caused problems by bringing men back to the house. Shresthova said her landlord made assumptions about her because she is half Nepalese. “That moment kind of drove back home to me how the layers work in different ways, and there’s yet another layer to peel back around assumptions [of] women’s roles,” Shresthova said. “It also was a moment where I was like … I’m going to stand up [for myself] here.”  Shresthova said that while she understands the importance of being culturally sensitive, she confronted her landlord and moved out that day because she didn’t want to support the landlord’s prejudiced beliefs, even if they were ingrained in his culture.  Brown said traveling to various countries that oppress women means having to take certain precautions to avoid being sexualized and abused. She said that in Egypt because of negative stereotypes toward Western women, she was instructed to wear a wedding ring and dress conservatively. Otherwise, she was told she would be “inviting men to touch [her].”  “When all the male experts left, and I was just chatting with them, they were like, ‘Actually, that time to walk was the time we had to hang out with each other and to speak,’” she said. “So something that would seem like a straightforward technological improvement to their lives was actually disrupting their female community.”  “I think it is irresponsible to some degree to not be engaged with your local community and to be engaged with these issues just internationally,” Carr said. “Though I think that obviously you should and can be doing both, but it is a good reminder for me that it’s not always productive for me as a Western woman to go into these other [countries] and be like, ‘This government, how could they do this?’” “How do you go into a refugee camp where someone has to get a pass to even be able to leave the immediate vicinity without risk of being jailed … how do you go in and then talk to them about gender mainstreaming and empowerment and agency?” Brown said.  (From left to right) Sangita Shresthova, Isabella Carr and Sara Brown discussed global women’s issues at the International Women’s Seminar Monday. (Julia Rosher/Daily Trojan) “[They] were not comfortable, it felt like they weren’t allowed to speak of it, a lot of it because they work in a small community and everyone would know,” Carr said. “Shame was something that came out a lot.”  She said it was difficult to teach ideas of gender equality and independence at a refugee camp where people must follow a strict schedule and rules to get food or leave the premises.  Panelists at the Price Women and Allies’ International Women’s Seminar discussed global issues women have continued to face domestically and abroad Monday at the Ronald Tutor Campus Center. The panel featured Sara Brown, a postdoctoral fellow at the USC Shoah Foundation; Sangita Shresthova, director of research of the Civic Imagination [email protected] at the Annenberg School for Communication and Journalism; and Isabella Carr, assistant director of the Levan Institute for Humanities and Ethics. PWA member Tanya Shah moderated the discussion. The panelists also discussed the main differences they noticed between America and the various countries where they visited and worked. Brown said she realized on a trip to a refugee camp in Tanzania that she has acted with a large amount of privilege and agency compared to women in other parts of the world.  Carr said it’s important to focus on solving local issues rather than criticizing international practices.  “At the time, I wanted to balk and say, ‘Well, I’ll do whatever I want,’ but at the same time, I was very mindful of the fact that the advice I was being given was advice from an informed source trying to protect me,” Brown said.   Carr said that women in America, especially after  #MeToo, are more open to sharing stories of sexual abuse than women in countries like Bosnia and Herzegovina. She said many of the Bosnian women refused to talk about the forcible rapes they endured for years while in captivity.last_img read more